Beta-blocker infusion did not improve left ventricular diastolic function in myocardial infarction: a Doppler

B Caramelli1, R D dos Santos, H Abensur

  • 1Heart Institute, University of São Paulo, Brazil.

Clinical Cardiology
|November 1, 1993
PubMed

Insights

Atenolol, a beta blocker, did not significantly improve left ventricular diastolic function in patients post-myocardial infarction. Hemodynamic changes observed suggest potential adverse effects on diastolic function despite some improvements in filling patterns.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Left ventricular (LV) diastolic dysfunction is a common complication following myocardial infarction.
  • Beta-blockers are hypothesized to improve diastolic function, particularly in patients with hypertension and heart failure.

Purpose of the Study:

  • To investigate the acute effects of atenolol on left ventricular diastolic function after anterior wall myocardial infarction.

Main Methods:

  • 32 patients with anterior wall myocardial infarction received intravenous atenolol (10 mg).
  • Doppler echocardiography and invasive hemodynamics were used to assess LV diastolic function before and after atenolol administration.

Main Results:

  • Atenolol administration led to a significant decrease in cardiac index and mean arterial pressure.
  • Pulmonary and systemic vascular resistance indices significantly increased post-atenolol.
  • Key diastolic parameters like peak late flow velocity decreased, while the early-to-late ratio and diastolic filling period increased.
  • Isovolumic relaxation time also showed a significant increase.

Conclusions:

  • Acute intravenous administration of atenolol did not improve, and may potentially worsen, left ventricular diastolic function in patients post-myocardial infarction.
  • The observed hemodynamic changes warrant further investigation into the role of beta-blockers in managing diastolic dysfunction post-MI.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...